69610-10-2

Basic information

• Product Name: 1-benzo[1,3]dioxol-5-yl-N-methyl-propan-2-amine
• Synonyms: 1-benzo[1,3]dioxol-5-yl-N-methyl-propan-2-amine;rac-(αR*)-N,α-Dimethyl-1,3-benzodioxole-5-(ethanamine)
• CAS NO: 69610-10-2
• Molecular Formula: C₁₁H₁₅NO₂
• Molecular Weight: 193.24
• Mol File: 69610-10-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 283.39 °C at 760 mmHg
• Flash Point: 113.23 °C
• Appearance: /
• Density: 1.1 g/cm³
• Vapor Pressure: 0.000272mmHg at 25°C
• CAS DataBase Reference: 1-benzo[1,3]dioxol-5-yl-N-methyl-propan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzo[1,3]dioxol-5-yl-N-methyl-propan-2-amine(69610-10-2)
• EPA Substance Registry System: 1-benzo[1,3]dioxol-5-yl-N-methyl-propan-2-amine(69610-10-2)

Safety Data

• Hazardous Substances Data: 69610-10-2(Hazardous Substances Data)

Usage

General Description

1-benzo[1,3]dioxol-5-yl-N-methyl-propan-2-amine, also known as 5-Methoxy-MDMA, is a chemical compound that is structurally related to the stimulant drug MDMA (3,4-methylenedioxymethamphetamine). It is a psychoactive substance known for its empathogenic and entactogenic effects, similar to those of MDMA. 5-Methoxy-MDMA is a substituted phenethylamine and a derivative of methamphetamine. It is commonly used as a recreational drug and is known to enhance sensory perceptions and create feelings of emotional closeness and empathy. However, it can also cause adverse effects such as increased heart rate, elevated blood pressure, and dehydration. Its legal status varies by country, with some prohibiting its use and others allowing it for limited medical uses or research purposes.

InChI:InChI=1/C11H15NO2.ClH/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10;/h3-4,6,8,12H,5,7H2,1-2H3;1H/t8-;/m0./s1

Upstream product

• 42542-10-9 3,4-methylenedioxymethamphetamine 
• 1616297-01-8 (R)-ethyl [1-(3,4-dibenzyloxyphenyl)propan-2-yl]carbamate 
• 1616296-98-0 (R,R_S)-N-[1-(3,4-dibenzyloxyphenyl)propan-2-yl]tertbutylsulfinamide 
• 62932-76-7 1-(3,4-bis(benzyloxy)phenyl)propan-2-one 
• 62932-96-1 (E)-1,2-dibenzyloxy-4-(2-nitroprop-1-en-1-yl)benzene 
• 5447-02-9 3,4-dibenzyloxybenzaldehyde 
• 1616297-03-0 (R)-ethyl 1-(benzo[d][1,3]dioxol-5-yl)propan-2-ylcarbamate 
• 1616297-02-9 (R)-ethyl [1-(3,4-dihydroxyphenyl)propan-2-yl]carbamate 
• 4764-17-4 (-)-Tenamfetamine 

Downstream Products

• 4764-17-4 (-)-Tenamfetamine 

Relevant articles and documents

Chiral separation of cathinone and amphetamine derivatives by HPLC/UV using sulfated β-cyclodextrin as chiral mobile phase additive

In the last years the identification of new legal and illegal highs has become a huge challenge for the police and prosecution authorities. In an analytical context, only a few analytical methods are available to identify these new substances. Moreover, many of these recreational drugs are chiral and it is supposed that the enantiomers differ in their pharmacological potency. Since nonenantioselective synthesis is easier and cheaper, they are mainly sold as racemic mixtures. The goal of this research work was to develop an inexpensive method for the chiral separation of cathinones and amphetamines. This should help to discover if the substances are sold as racemic mixtures and give further information about their quality as well as their origin. Chiral separation of a set of 6 amphetamine and 25 cathinone derivatives, mainly purchased from various Internet shops, is presented. A LiChrospher 100 RP-18e, 250 x 4 mm, 5 μm served as the stationary phase. The chiral mobile phase consisted of methanol, water, and sulfated β-cyclodextrin. Measurements were performed under isocratic conditions in reversed phase mode using UV detection. Four model compounds of the two substance classes were used to optimize the mobile phase. Under final conditions (methanol:water 2.5:97.5 + 2% sulfated β-cyclodextrin) enantiomers of amphetamine and five derivatives were baseline separated within 23 min. In all, 17 cathinones were completely or partially chirally separated. However, as only 3 of 25 cathinones were baseline resolved, the application of this method is limited for cathinone analogs. Additionally, the results were compared with an RP-8e column. Copyright

Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: Representatives of a novel therapeutic class

The α-ethyl phenethylamine derivative 1-(1,3-benzodioxol-5-yl)-2-butanamine was prepared. An asymmetric synthesis was used to prepare the enantiomers of this compound and the related α-methyl homologue (MDA). The racemates and enantiomers of both compounds were evaluated in the two-lever drug discrimination assay in rats trained to discriminate saline from 0.08 mg/kg of LSD tartrate. Stimulus generalization occurred with the racemate and the R-(-)enantiomer of the α-methyl homologue and the S-(+)enantiomer of the α-ethyl primary amine. No generalization occurred with the other enantiomers or with the N-methyl derivatives of either series. Human psychopharmacology studies revealed that the N-methyl derivative of the title compound was nonhallucinogenic and that it had a new, novel psychoactive effect. It is suggested that this compound is the prototype of a new pharmacologic class that may have value in facilitating psychotherapy and that this class be designated as entactogens.